Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Jul 20, 2021 (5 years ago)

Miss Slim

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Marketed without ANDA/NDA approval

Cause type: Other

Recalls whose stated reason does not fall into the categories above. See the recall's own reason text for the specifics. All other recalls.

What was recalled

Miss Slim, capsules, packaged in 10-count and 30-count box, Distributed by : His Enterprise Made in USA UPC 742137605030

Recalling firm
His Enterprise INC
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0770-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other other recalls from 2021

All other recalls
Class II · Moderate risk

Hydroquinone USP

Finished product specification did not meet USP specifications.

Terminated Other Monarch PCM, LLC NDC 69367-174-01 D-0855-2021
Class II · Moderate risk

Carvedilol 25 mg

A 500 count bottle of Carvedilol 25 mg tablets contained two Paroxetine Tablets, 40 mg. Product was repackaged into 180 count bottles.

Terminated Other RemedyRepack Inc. NDC 68382-0095-05 D-0754-2021
Class III · Low risk

Asenapine Sublingual Tablets

Incorrect Product Formulation; product was manufactured with the incorrect Art Cherry Flavor flavoring agent instead of Art Black Cherry Flavor flavoring agent

Terminated Other SigmaPharm Laboratories LLC NDC 42794-017-10 D-0380-2021
Class III · Low risk

Asenapine Sublingual Tablets

Incorrect Product Formulation; product was manufactured with the incorrect Art Cherry Flavor flavoring agent instead of Art Black Cherry Flavor flavoring agent

Terminated Other SigmaPharm Laboratories LLC NDC 42794-016-10 D-0379-2021